Benicar and Bronchitis chronic - a phase IV clinical study of FDA data

Summary:

Bronchitis chronic is reported as a side effect among people who take Benicar (olmesartan medoxomil), especially for people who are female, 40-49 old, have been taking the drug for 2 - 5 years also take Benicar Hct, and have Chronic obstructive pulmonary disease.

The phase IV clinical study analyzes which people have Bronchitis chronic when taking Benicar. It is created by eHealthMe based on reports of 34,073 people who have side effects when taking Benicar from the FDA, and is updated regularly.

What is Benicar?

Benicar has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 36,002 Benicar users. Check the latest studies of Benicar.

What is Bronchitis chronic?

Bronchitis chronic (inflammation of the mucous membrane in the bronchial tubes- chronic) is found to be associated with 566 drugs and 543 conditions by eHealthMe. Check the latest studies of Bronchitis chronic.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

34,073 people reported to have side effects when taking Benicar.
Among them, 39 people (0.11%) have Bronchitis chronic.

Among these 39 people:

How long have people been on Benicar when they have Bronchitis chronic? *

What is the gender of people who have Bronchitis chronic when taking Benicar? *

female: 90 %
male: 10 %

What is the age of people who have Bronchitis chronic when taking Benicar? *

What are other drugs people take besides Benicar? *

What are other side effects people have besides Bronchitis chronic? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 27 people, 69.23%
Weight Decreased: 16 people, 41.03%
Hypokalemia (low potassium): 13 people, 33.33%
Dizziness: 11 people, 28.21%
Hiatal Hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm): 11 people, 28.21%
Diarrhea: 10 people, 25.64%
Diverticulum (out pouching of a hollow (or a fluid-filled) structure in the body): 10 people, 25.64%
Hepatic Steatosis (fatty liver disease): 10 people, 25.64%
Gastritis (inflammation of stomach): 9 people, 23.08%
Haemorrhoids (a swollen vein or group of veins in the region of the anus): 9 people, 23.08%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 10.26%
Indigestion: 4 people, 10.26%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 10.26%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 4 people, 10.26%
Insomnia (sleeplessness): 3 people, 7.69%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 3 people, 7.69%
Cardiac Disorder: 3 people, 7.69%
High Blood Cholesterol: 2 people, 5.13%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 2 people, 5.13%
Pain: 1 person, 2.56%

* Approximation only. Some reports may have incomplete information.

Do you take Benicar and have Bronchitis chronic?

- Check whether Bronchitis chronic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Benicar:

Benicar (36,002 reports)

Browse all side effects of Benicar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bronchitis chronic:

Bronchitis chronic (566 drugs)

Browse all the conditions that are associated with Bronchitis chronic:

Bronchitis chronic (543 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil (the active ingredients of Benicar) and Benicar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.